What are the indications, pharmacokinetics, and recommended dosing regimen for Novolin R (regular insulin) in adults?

Novolin R (Regular Human Insulin): Clinical Overview

Novolin R is a short-acting human insulin indicated for glycemic control in adults and pediatric patients with diabetes mellitus, administered subcutaneously 30 minutes before meals or intravenously under medical supervision. 1

Indications

Novolin R is FDA-approved to improve glycemic control in both adults and children with diabetes mellitus 1. It serves as a prandial (mealtime) insulin and can be used in diabetic ketoacidosis (DKA) management when administered intravenously.

Pharmacokinetics and Pharmacodynamics

Onset and Duration

• Subcutaneous administration: Onset approximately 30 minutes post-injection, peak effect at 1.5-3.5 hours, duration approximately 8 hours 1
• Intravenous administration: More rapid onset compared to subcutaneous route 1
• Peak insulin concentrations: Occur between 1.5-2.5 hours after subcutaneous injection 1

Critical distinction: Novolin R has a slower onset and longer duration compared to rapid-acting insulin analogs (lispro, aspart, glulisine) 2. This pharmacodynamic profile makes timing crucial—it must be given 30 minutes before meals, unlike rapid-acting analogs that can be given immediately before eating.

Dosing Regimens

Outpatient Type 2 Diabetes Management

For insulin-naive patients initiating therapy 3:

• Calculate total daily dose (TDD):

  • 0.2-0.3 units/kg/day for patients ≥70 years or GFR <60 mL/min
  • 0.4 units/kg/day for blood glucose 140-200 mg/dL
  • 0.5 units/kg/day for blood glucose 201-400 mg/dL

• Distribute as 50% basal insulin (NPH or long-acting analog) and 50% prandial insulin (regular insulin like Novolin R)

• Divide prandial component into three equal doses before meals 3

Titration approach 4:

• Start with one prandial dose before the largest meal (4 units or 10% of basal dose)
• Increase by 1-2 units or 10-15% twice weekly based on postprandial glucose
• If hypoglycemia occurs without clear cause, reduce corresponding dose by 10-20%

Hospitalized Patients (Non-Critical Care)

Basal-bolus regimen 3, 5:

• Preferred over sliding scale insulin (SSI) alone, which should be avoided as sole therapy
• Regular insulin given before meals with correction doses
• If patient is NPO: Give regular insulin every 6 hours for correction doses (versus every 4 hours for rapid-acting analogs) 3

Correction insulin scale 3: For patients eating meals, use regular insulin before each meal following this typical dosing:

• Blood glucose 141-180 mg/dL: 4 units (usual column)
• Blood glucose 181-220 mg/dL: 6 units
• Blood glucose 221-260 mg/dL: 8 units
• Blood glucose 261-300 mg/dL: 10 units
• Blood glucose 301-350 mg/dL: 12 units
• Blood glucose 351-400 mg/dL: 14 units
• Blood glucose ≥400 mg/dL: 16 units

Use insulin-sensitive column (lower doses) for elderly, those not eating, or with renal impairment 3.

Diabetic Ketoacidosis (DKA)

For mild DKA 6:

• "Priming" dose: 0.4-0.6 units/kg body weight (half IV bolus, half subcutaneous/IM)
• Maintenance: 0.1 unit/kg subcutaneously or intramuscularly every hour
• Continue until glucose ≤200 mg/dL, bicarbonate ≥18 mEq/L, venous pH ≥7.3

For moderate-severe DKA: Continuous IV infusion is preferred over subcutaneous administration 6.

Intravenous Administration

Only under medical supervision 1:

• Dilute to concentrations of 0.05-1 unit/mL in polypropylene infusion bags
• Compatible with 0.9% sodium chloride, 5% dextrose, or 10% dextrose with 40 mmol/L potassium chloride
• Stable at room temperature for 24 hours 1
• Requires close monitoring of blood glucose and potassium levels

Administration Technique

Subcutaneous Injection

• Timing: Inject 30 minutes before meal start 1
• Sites: Abdominal area (preferred for fastest absorption), buttocks, thigh, or upper arm
• Rotation: Rotate sites within same region to reduce lipodystrophy and localized cutaneous amyloidosis risk 1
• Never inject into areas of lipodystrophy as this affects absorption 1

Mixing with Other Insulins

• Can be mixed with NPH (Novolin N) 1
• Draw Novolin R first, then NPH into the same syringe
• Inject immediately after mixing 1

Critical safety point: Novolin R should NOT be used in insulin pumps due to precipitation risk 1.

Special Populations

Renal Impairment

• Increased hypoglycemia risk 1
• Requires more frequent dose adjustments and glucose monitoring
• Use lower initial doses (0.2-0.3 units/kg/day) 3

Hepatic Impairment

• Increased hypoglycemia risk 1
• More frequent monitoring and dose adjustments needed

Elderly (≥70 years)

• Start with lower doses: 0.2-0.3 units/kg/day 3
• Use insulin-sensitive correction scale 3

Key Warnings and Precautions

Hypoglycemia

• Most common adverse reaction 1
• Risk factors: renal/hepatic impairment, elderly age, hypoglycemia unawareness, changes in meal patterns or physical activity
• Management: Oral glucose if able to swallow; subcutaneous/IM/intranasal glucagon if unresponsive 7

Medication Errors

• Never share FlexPens or syringes between patients, even with needle changes—risk of blood-borne pathogen transmission 1
• Always check insulin labels before administration to prevent mix-ups with other insulin products 1

Hypokalemia

• Can be life-threatening, especially with IV administration 1
• Monitor potassium levels in at-risk patients

Drug Interactions

• Antiadrenergic drugs (beta-blockers, clonidine): May mask hypoglycemia symptoms 1
• Multiple medications affect glucose metabolism—dose adjustments may be needed 1

Available Formulations

• 10 mL multiple-dose vial (100 units/mL) 1
• 3 mL FlexPen prefilled pen (100 units/mL, dials in 1-unit increments) 1

Storage

• Unopened: Refrigerate (36-46°F) until expiration date 1
• Opened vials: 42 days at room temperature up to 77°F (do not refrigerate) 1
• Opened FlexPens: 28 days at room temperature up to 86°F (do not refrigerate) 1
• Never freeze; discard if frozen 1

Clinical Context and Alternatives

Novolin R is less expensive than rapid-acting insulin analogs but requires stricter meal timing (30 minutes before vs. immediately before) 2. Current guidelines favor rapid-acting analogs for prandial coverage due to superior pharmacodynamic profiles, but regular insulin remains a cost-effective alternative when analog insulins are not accessible 8, 2.

For type 2 diabetes intensification, guidelines now recommend considering GLP-1 receptor agonists before adding prandial insulin due to lower hypoglycemia risk and weight benefits 8, 4. However, when prandial insulin is needed and cost is a barrier, Novolin R provides effective glycemic control with proper patient education about timing.